It will grow to $9.02 billion in 2029 at a compound annual growth rate (CAGR) of 15.3%.” — The Business Research Company LONDON, GREATER LONDON, UNITED KINGDOM, July 3, 2025 /EINPresswire.com/ -- Save ...

Novartis is on the final straight to approval of its spinal muscular atrophy (SMA) gene therapy Zolgensma in the EU, after getting a recommendation for approval from the CHMP. The positive opinion ...

Both drugs are designed to switch on the SMN2 gene, to compensate for the loss of the SMN1 gene that isn't working properly in SMA, but Novartis found that its drug also worked on another gene ...

Paraphase – a computational tool that accurately resolves and analyzes paralogous genes – unlocks the difficult-to-analyze ...

Gene Demby is a founding member of NPRs Code Switch team, where he serves as a host of the show's podcast. In 2020, Code Switch was named Apple's inaugural Podcast Of The Year. Demby's essays for ...

Gene expression is the generation of a functional gene product from the information encoded by a gene, through the processes of transcription and translation. Gene products are often proteins ...

The disease is caused by mutations in the SMN1 (survival motor neuron) gene. People who develop SMA must inherit two faulty SMN1 genes, one from each parent. Kirsten and John had no idea until ...

Treatment with salanersen slowed neurodegeneration and improved motor function in children with SMA in a Phase 1 trial, ...